epocrates logo
epocrates logo
epocrates logo
  • 0

Diseases

Evaluation of urticaria

OVERVIEW

  • Summary
  • Urgent Considerations
  • Etiology

DIAGNOSIS

  • Differential Diagnosis
  • Diagnostic Approach

IMAGES

  • Library

REFERENCES

  • Citations
  • Credits

Summary

AAFont SizeShareMore Information
Urticaria, also known as welts, hives, or wheals, is characterized by the appearance of intensely pruritic erythematous plaques.[1] It appears clinically as pruritic, pale, blanching swellings of the superficial dermis that last for up to 24 hours. Lesions may be small, large, giant, oval, or annular.Images
Urticaria affects 10% to 25% of the population and can occur in any age group.[2]​​ It is a mast-cell-driven disease. The triggering mechanisms for mast-cell activation in urticaria are not well defined but seem to be multiple and diverse.[3]
Urticaria is classified according to duration of symptoms:
  • Acute urticaria: the occurrence of spontaneous wheals, angioedema, or both for <6 weeks[1] [2] [3]​​​​

  • Chronic urticaria: urticaria that has been continuously or intermittently present for ≥6 weeks.​[1] [3] [4]

Chronic urticaria is classified into 2 subtypes:[3]​
  • Chronic spontaneous urticaria: spontaneous appearance of wheals, angioedema, or both ≥6 weeks due to known or unknown causes.

  • Inducible urticaria, for example delayed pressure urticaria, heat urticaria, solar urticaria, symptomatic dermatographism, vibratory angioedema, aquagenic urticaria, cholinergic urticaria, and contact urticaria.

Urticaria complicated by angioedema
Some people have urticaria that is complicated by angioedema, a swelling of the deeper dermis and tissues (e.g., mucosal surfaces), with laryngeal edema potentially causing respiratory distress and death.[3]​ Angioedema is commonly associated with urticaria and may occur at any age.[5] It may not necessarily be seen at the first urticarial episode, but risk of angioedema increases with greater exposure to the allergenic substance.[6]
Clinical presentation of angioedema may include nonpitting edema of the subcutaneous tissues involving lips, face, neck and extremities and/or submucosal tissues affecting the oral cavity, larynx and gastrointestinal system.[7]​ Associated symptoms may also be present. These are dependent on the underlying etiology. Examples include flushing, bronchospasm, abdominal pain, diarrhea and vomiting.[7]​ Angioedema without urticaria should prompt further evaluation.[1]Image
content by BMJ Group
Last updated

Library

  • Acute urticaria: typical wheals

    Acute urticaria: typical wheals

  • Typical lesions seen in acute or chronic urticaria

    Typical lesions seen in acute or chronic urticaria

  • Urticaria: wheals

    Urticaria: wheals

  • Angio-oedema of the lips in a patient who also has urticaria

    Angio-oedema of the lips in a patient who also has urticaria

  • Palmar target lesions

    Palmar target lesions

  • Stevens-Johnson syndrome: targetoid lesion and epidermal loss

    Stevens-Johnson syndrome: targetoid lesion and epidermal loss

  • Dermatographism

    Dermatographism

Citations

    Key Articles

    • Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014 May;133(5):1270-7.[Abstract]

    • European Dermatology Forum. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Sep 2021 [internet publication].[Full Text]

    • Sabroe RA, Lawlor F, Grattan CEH, et al. British Association of Dermatologists guidelines for the management of people with chronic urticaria 2021. Br J Dermatol. 2022 Mar;186(3):398-413.[Abstract][Full Text]

    • Moellman JJ, Bernstein JA, Lindsell C, et al. A consensus parameter for the evaluation and management of angioedema in the emergency department. Acad Emerg Med. 2014 Apr;21(4):469-84.[Abstract][Full Text]

    Referenced Articles

    • 1. Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014 May;133(5):1270-7.[Abstract]

    • 2. Guldbakke KK, Khachemoune A. Etiology, classification, and treatment of urticaria. Cutis. 2007 Jan;79(1):41-9.[Abstract]

    • 3. European Dermatology Forum. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Sep 2021 [internet publication].[Full Text]

    • 4. Sabroe RA, Lawlor F, Grattan CEH, et al. British Association of Dermatologists guidelines for the management of people with chronic urticaria 2021. Br J Dermatol. 2022 Mar;186(3):398-413.[Abstract][Full Text]

    • 5. Katelaris CH, Peake JE. MJA practice essentials 5. Allergy and the skin: eczema and chronic urticaria. Med J Aust. 2006 Nov 6;185(9):517-22.[Abstract][Full Text]

    • 6. Grattan CEH, Black AK. Urticaria and angioedema. In: Bolognia JL, Jorizzo JL, Rapini RP ed. Dermatology (volume one). London, UK: Mosby; 2003;287-302.

    • 7. Depetri F, Tedeschi A, Cugno M. Angioedema and emergency medicine: From pathophysiology to diagnosis and treatment. Eur J Intern Med. 2019 Jan;59:8-13.[Abstract]

    • 8. ​World Allergy Organization. Latex allergy diagnosis and management. Jan 2022 [internet publication].[Full Text]

    • 9. ​​DermNet. Drug-induced urticaria. Feb 2020 [internet publication].[Full Text]

    • 10. Kim DH, Sung NH, Lee AY. Effect of levothyroxine treatment on clinical symptoms in hypothyroid patients with chronic urticaria and thyroid autoimmunity. Ann Dermatol. 2016 Apr;28(2):199-204.[Abstract][Full Text]

    • 11. Carter MC, Metcalfe DD, Komarow HD. Mastocytosis. Immunol Allergy Clin North Am. 2014 Feb;34(1):181-96.[Abstract]

    • 12. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: systemic mastocytosis [internet publication].[Full Text]

    • 13. Hartmann K, Escribano L, Grattan C, et al. Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma and Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol. 2016 Jan;137(1):35-45.[Abstract][Full Text]

    • 14. Zuberbier T, Bernstein JA. A comparison of the United States and international perspective on chronic urticaria guidelines. J Allergy Clin Immunol Pract. 2018 Jul - Aug;6(4):1144-51.[Abstract][Full Text]

    • 15. Weiler CR, Austen KF, Akin C, et al. AAAAI Mast Cell Disorders Committee Work Group report: Mast cell activation syndrome (MCAS) diagnosis and management. J Allergy Clin Immunol. 2019 Oct;144(4):883-96.[Abstract][Full Text]

    • 16. Kulthanan K, Jiamton S, Thumpimukvatana N, et al. Chronic idiopathic urticaria: prevalence and clinical course. J Dermatol. 2007 May;34(5):294-301.[Abstract]

    • 17. Zuberbier T, Maurer M. Urticaria: current opinions about etiology, diagnosis and therapy. Acta Derm Venereol. 2007;87(3):196-205.[Abstract]

    • 18. Irinyi B, Szeles G, Gyimesi E, et al. Clinical and laboratory examinations in the subgroups of chronic urticaria. Int Arch Allergy Immunol. 2007;144(3):217-25.[Abstract]

    • 19. Kaplan AP. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol. 2004 Sep;114(3):465-74.[Abstract][Full Text]

    • 20. Liu JB, Li M, Yang S, et al. Clinical profiles of vitiligo in China: an analysis of 3742 patients. Clin Exp Dermatol. 2005 Jul;30(4):327-31.[Abstract]

    • 21. Resuscitation Council UK. Emergency treatment of anaphylactic reactions: Guidelines for healthcare providers. 2021 [internet publication].[Full Text]

    • 22. Shaker MS, Wallace DV, Golden DBK, et al. Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol. 2020 Apr;145(4):1082-23.[Abstract][Full Text]

    • 23. Golden DBK, Wang J, Waserman S, et al. Anaphylaxis: a 2023 practice parameter update. Ann Allergy Asthma Immunol. 2024 Feb;132(2):124-76.[Abstract][Full Text]

    • 24. Lott C, Truhlář A, Alfonzo A, et al. European Resuscitation Council guidelines 2021: cardiac arrest in special circumstances. Resuscitation. 2021 Apr;161:152-219.[Abstract][Full Text]

    • 25. Cardona V, Ansotegui IJ, Ebisawa M, et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J. 2020 Oct;13(10):100472.[Abstract][Full Text]

    • 26. Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021 Jan;9(1):132-50.[Abstract][Full Text]

    • 27. Betschel S, Badiou J, Binkley K, et al. The International/Canadian hereditary angioedema guideline. Allergy Asthma Clin Immunol. 2019;15:72.[Abstract][Full Text]

    • 28. Matos AL, Figueiredo C, Gonçalo M. Differential diagnosis of urticarial lesions. Front Allergy. 2022;3:808543.[Abstract][Full Text]

    • 29. Hayat H, Ahmed Q, Alam H, et al. Non-severe allergic transfusion reaction: A hidden cause of wastage of blood product and laboratory resources. Vox Sang. 2023 Mar;118(3):193-8.[Abstract]

    • 30. Shipley D, Ormerod AD. Drug-induced urticaria. Recognition and treatment. Am J Clin Dermatol. 2001;2(3):151-8.[Abstract][Full Text]

    • 31. Moellman JJ, Bernstein JA, Lindsell C, et al. A consensus parameter for the evaluation and management of angioedema in the emergency department. Acad Emerg Med. 2014 Apr;21(4):469-84.[Abstract][Full Text]

    • 32. Schoepke N, Młynek A, Weller K, et al. Symptomatic dermographism: an inadequately described disease. J Eur Acad Dermatol Venereol. 2015 Apr;29(4):708-12.[Abstract]

    • 33. Breathnach SM, Allen R, Ward AM, et al. Symptomatic dermographism: natural history, clinical features laboratory investigations and response to therapy. Clin Exp Dermatol. 1983 Sep;8(5):463-76.[Abstract]

    • 34. Kontou-Fili K, Borici-Mazi R, Kapp A, et al. Physical urticaria: classification and diagnostic guidelines. An EAACI position paper. Allergy. 1997 May;52(5):504-13.[Abstract]

    • 35. Sicherer SH, Teuber S, Adverse Reactions to Foods Committee. Current approach to the diagnosis and management of adverse reactions to foods. J Allergy Clin Immunol. 2004 Nov;114(5):1146-50.[Abstract][Full Text]

    • 36. Godse K, De A, Zawar V, et al. Consensus statement for the diagnosis and treatment of urticaria: a 2017 update. Indian J Dermatol. 2018 Jan-Feb;63(1):2-15.[Abstract][Full Text]

    • 37. Hawro T, Ohanyan T, Schoepke N, et al. The urticaria activity score-validity, reliability, and responsiveness. J Allergy Clin Immunol Pract. 2018 Jul - Aug;6(4):1185-90.[Abstract][Full Text]

    • 38. Schwartz LB, Irani AM. Serum tryptase and the laboratory diagnosis of systemic mastocytosis. Hematol Oncol Clin North Am. 2000 Jun;14(3):641-57.[Abstract]

    • 39. Valent P, Akin C. Doctor, I think I am suffering from MCAS: differential diagnosis and separating facts from fiction. J Allergy Clin Immunol Pract. 2019 Apr;7(4):1109-14.[Abstract][Full Text]

    • 40. Valent P, Akin C, Bonadonna P, et al. Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome. J Allergy Clin Immunol Pract. 2019 Apr;7(4):1125-33.e1.[Abstract][Full Text]

    • 41. Theoharides TC, Valent P, Akin C. Mast cells, mastocytosis, and related disorders. N Engl J Med. 2015 Jul 9;373(2):163-72.[Abstract]

    • 42. National Institute for Health and Care Excellence. Anaphylaxis: assessment and referral after emergency treatment. Aug 2020 [internet publication].[Full Text]

    • 43. Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med. 1992 Aug 6;327(6):380-4.[Abstract][Full Text]

Have feedback?
Tell us about your experience
Scroll to Top
epocrates logo

Sign in to access our clinical decision support tools

Sign inCreate Account
Download Epocrates from the App StoreDownload Epocrates from the Play Store
About UsFeaturesBusiness SolutionsHelp & Feedback
© 2026 epocrates, Inc.   Terms of UsePrivacy PolicyEditorial PolicyDo Not Sell or Share My Information